The stem cells and acute respiratory
The acute respiratory syndromes, majorly affecting the lungs and their efficacy have haunted the world in the last decades with MERS-CoV, SARS-COV, and SARS-CoV-2. Researchers across different corners of the world are trying to understand the relationship between immune dysregulation and disease pathophysiology. While currently, the spread of infection is at major set backstage due to the development of vaccines, scientists are still trying to understand the disease at the cellular and the molecular levels, wherein the cell culture models play a vital role.
We have discovered that primary cells and stem cells can be worked out as excellent cell culture models, possessing the characteristic features of the donors. While our range of cell lines has made a significant contribution during the vaccine development, we are also thrilled to present a range of primary cells, media, and other supportive products for understanding acute respiratory distress syndrome.
So far, 7 different types of coronaviruses have been documented causing acute respiratory distress syndrome; with a different set of genetic heterogeneity and immunological aspects. This genetic complexity coupled with the dwindling supply of antiviral treatment necessitates the need for the development of effective screening and enrichment methods of viruses using suitable in vitro model systems. However, the development of novel vaccines and effective antiviral treatments is currently challenged by multiple issues like batch-to-batch variation, contamination, unavailability of effective primary cells for screening purposes, etc.
At Kosheeka, we believe that it takes the combined efforts of dedicated scientists across the world to discover therapeutic modalities that are needed to maintain the health and safety of humankind. This provokes us to be committed to offering multiple ranges of virus-producing cell lines, primary cells, and stem cells for therapeutic screening.
Accordingly, Kosheeka’s portfolio for acute respiratory distress syndrome includes:
- Range of primary cells for respiratory research, including vascular and microvascular endothelial cells, airway epithelial cells, smooth muscle cells, etc.
- Wide range of primary stem cells to support the therapeutic development of COVID-19, which include mesenchymal stem cells isolated from human umbilical cord Wharton’s jelly. Exosomes isolated from mesenchymal stem cells etc.
- Essential cell culture growth medium for optimized growth and culture.
During the pandemic and in the post-pandemic era, multiple labs and pharmaceutical companies around the globe are relying on our primary cells and stem cells for both vaccine development and development of the therapeutic module.